Localized extremity soft tissue sarcoma: towards a patient-tailored approach
Stevenson, Marc Gilliam

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2018

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Hyperthermic isolated limb perfusion, preoperative radiotherapy, and surgery (PRS) a new limb saving treatment strategy for locally advanced sarcomas
Abstract

Background

This feasibility study presents the results of a new intensive treatment regimen for locally advanced extremity soft tissue sarcomas (ESTS), consisting of hyperthermic isolated limb perfusion (HILP), preoperative external beam radiotherapy (EBRT) and surgical resection.

Methods

From 2011 to 2016, 11 high grade locally advanced ESTS patients underwent this treatment regimen. Preoperative EBRT (12x3 Gy) started <4 weeks following the HILP (TNF-α and melphalan) and the surgical resection was planned to take place <2 weeks following the end of the EBRT.

Results

All patients completed the treatment. After a median follow-up of 32 (23-50) months, the limb was saved in 10 patients (91%), 1 patient (9%) developed a local recurrence, 5 patients (45%) developed distant metastases and 3 patients (27%) died of their disease. During follow-up two patients (18%) developed a pathologic fracture of the treated limb and three patients (27%) developed a major wound complication requiring surgical intervention. The median overall treatment time (OTT) was 56 (49-69) days.

Conclusions

This intensive treatment regimen is feasible and safe in locally advanced ESTS, and it achieves oncological results that are comparable with conventional HILP treatment. In addition, the major wound complication risk is comparable and the OTT is reduced.

Introduction

Annually, approximately 600-700 patients are diagnosed with soft tissue sarcoma (STS) in The Netherlands, making it a relatively rare malignancy which accounts for less than 1% of all cancers in adults. In patients with extremity soft tissue sarcoma (ESTS), amputation does not improve survival rates. Thus limb salvage treatment has become increasingly important over the years and neoadjuvant treatment regimens have been developed to prevent limb amputation in locally advanced ESTS. In the 1990s, there was renewed interest in hyperthermic isolated limb perfusion (HILP), originally developed by Creech et al. in 1957, for treating locally advanced ESTS. Initially, interferon-γ (IFN) and tumor necrosis factor-α (TNF-α) were added to the commonly used melphalan perfusate. However, IFN was soon abandoned due to ineffectiveness. The addition of TNF-α however, led to high response rates and limb preservation, and eventually to the approval of TNF-α in Europe, resulting in over 40 centers using HILP in the treatment of locally advanced ESTS.

Since 1991, patients with locally advanced ESTS have been treated at the University Medical Center Groningen (UMCG) with neoadjuvant HILP followed by delayed surgical resection, and postoperative external beam radiotherapy (EBRT) when indicated. Hoven-Gondrie et al. described this cohort of 113 patients, of which 63 patients (56%) underwent HILP, surgery, and postoperative EBRT and 50 patients (44%) underwent HILP and surgery alone. This conventional perfusion treatment is extensive, long lasting, and the recovery and waiting time between the different treatment stages is long (six to eight weeks between neoadjuvant HILP and surgical resection and another six to eight weeks between surgical resection and the start of the postoperative EBRT, resulting in an overall median treatment time of 22 (20-24) weeks (including the postoperative EBRT). Due to the postoperative timing of the EBRT, radiation schemes are long and high doses are administered i.e. 30-35x2 Gy. A follow-up study performed at the UMCG showed serious long-term treatment induced morbidity in 63% of patients. Moreover, the long-term morbidity tends to be higher in postoperative irradiated patient as compared with preoperative EBRT in ESTS. The standard preoperative EBRT dose for ESTS is 50 Gy given in 25 daily fractions of 2 Gy, however, several studies have been conducted combining preoperative hypofractionated EBRT with neoadjuvant chemotherapy.
At the UMCG a new intensive treatment regimen consisting of Perfusion, hypofractionated preoperative Radiotherapy and Surgery (PRS) for locally advanced ESTS was investigated with the ultimate goal to reduce the short- and long-term treatment-induced morbidity and to reduce the overall treatment time (OTT) while achieving comparable oncological outcome. The results of this treatment regimen are presented in this feasibility study.

**Materials and methods**

**Patients**

From 2011 to 2016, 11 patients, nine males and two females with a median age of 64 (44–74) years were included in this novel, Institutional Review Board (IRB) approved, treatment regimen (IRB protocol review case-number 2010.299). Patients diagnosed with a primarily non-resectable (locally advanced), non-metastatic, high grade ESTS were included in this study. At the UMCG all sarcoma patients are presented and discussed in a weekly multidisciplinary sarcoma team meeting. Accordingly, patients eligible for HILP treatment were included in the PRS treatment regimen based on a tumor board decision. Data were prospectively collected and retrospectively analyzed. The PRS treatment consisted of neoadjuvant HILP, preoperative hypofractionated EBRT, followed by surgical resection with plastic surgical reconstruction when required. All patients were treated by a rehabilitation specialist and/or physiotherapist prior to, during, and after the treatment course, to optimize the functional treatment outcome. Follow-up ended at death or April 30, 2017. Data concerning demographics, tumor characteristics, comorbidity, hospitalization and follow-up were collected from medical records. The OTT was defined as the time between HILP and surgical resection and was used as marker to estimate the extent of treatment.

**Perfusion**

The HILP procedure at the UMCG is based on the procedure developed by Creech et al. The operation was performed under general anesthesia. An incision was made, and the major artery and vein of the leg were isolated, collateral vessels ligated, and 3.3 mg heparin per kg bodyweight was given intravenously. The blood flow of the leg was isolated from the systemic circulation by cannulating the main artery and vein and connecting it to an extracorporeal circuit. Subsequently, a tourniquet was applied to minimize leakage of TNF-α (Beromun®, Boehringer-Ingelheim GmbH, Vienna, Austria) and/or melphalan (Alkeran®, GlaxoSmithKline Pharmaceuticals, Research Triangle Park, NC, USA) into the systemic circulation. A precordial scintillation detector and ¹³¹I-human serum albumin were used to continuously measure the leakage into the systemic circulation. The ILP was performed under controlled mild hyperthermia (38.5-40.0°C). For upper extremity and popliteal perfusions, 1 mg TNF-α was used; while, 2 mg was used for iliac or femoral perfusions. After 15 min of TNF-α perfusion, melphalan (10 mg/L limb volume for upper extremity and popliteal perfusions and 13 mg/L for iliac and femoral perfusions) was added. After another 45 min, the limb was washed with 2 L (for upper extremity and popliteal perfusions) or 6 L (iliac/femoral) of saline. Afterwards, the limb was filled with red blood cell concentrate (1 U). The canulas were removed, the vessels repaired, and the heparin antagonized with protamine sulphate. To prevent a compartment syndrome, a closed fasciotomy of the anterior compartment of the lower leg was performed. The patient was closely observed in the intensive care unit for the first 24 hours following the procedure. The complete perfusion technique and leakage monitoring have been previously described in more detail.

**Radiotherapy**

To complete the neoadjuvant therapy, patients were treated with preoperative hypofractionated PET-CT guided EBRT, which was planned to start 4 weeks after HILP. Patients underwent an FDG PET-CT in radiation position to delineate the tumor, and to obtain gross tumor and planning target volumes (Figure 1). Intensity modulated radiotherapy was delivered with a linear accelerator in a hypofractionated schedule of 12x3 Gy.

---

**Figure 1.** Delineation of a soft tissue sarcoma of the knee. In green the gross tumor volume and in red the planning target volume. On the left: a MRI scan fused to the radiotherapy planning CT-scan is shown, while on the right the FDG PET-CT scan is used for the delineation.
Resection
After completion of the preoperative EBRT, the surgical resection was scheduled to take place within 2 weeks. Since only patients with locally advanced ESTS were included, extensive surgical resections were performed. To achieve wound closure, plastic surgical reconstructions were performed when required. Excision was classified as Ro when the resection margins were microscopically free of tumor cells, as Rh when resection margins were involved microscopically, and as R2 when resection margins were macroscopically comprised. Complications that occurred during treatment or within 120 days following the surgical resection were noted and classified according to Clavien-Dindo. Wound complications requiring surgical intervention were defined as major wound complication.

Histopathologic examination
Prior to treatment, a core needle biopsy was performed for histopathologic typing and grading of the tumor. All pathologic specimens were re-evaluated in 2017 by a pathologist with expertise in STS. The histopathologic tumor response to neoadjuvant treatment was determined following recently published European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations. As follows: Grade A, no stainable tumor cells left; Grade B, single stainable tumor cells or small clusters (overall <1% left); Grade C, ≥1% - 10% stainable tumor cells left; Grade D, ≥10% - <50% stainable tumor cells left; and Grade E, ≥50% stainable tumor cells left.

Statistical analysis
All variables were summarized with frequencies and percentages for discrete variables and medians and interquartile ranges (IQRs) for continuous variables; none of the variables were normally distributed. SPSS Version 22.0 (IBM SPSS Statistics for Windows, Version 22.0 Armonk, NY: IBM Corp) was used for statistical analyses.

Results
All 11 patients, 9 males (82%) and 2 females (18%) with a median age 64 (44-74) years completed the scheduled PRS treatment regimen and all tumors were resectable following the neoadjuvant HILP and preoperative EBRT (Table 1). All tumors were high grade. Due to vascular involvement, one patient (9.1%) needed a vascular reconstruction following the surgical resection of the tumor remnant. Direct plastic surgical reconstructions were performed in three patients (27%) to obtain wound closure. Histopathologic examination of the resected specimens showed six Ro (55%), four Rh (36%) and one R2 resections (9%). The neoadjuvant treatment-induced tumor responses were: one grade A (9%), one grade B (9%), two grade C (18%), five grade D (45%), and two grade E (18%). A total of 14 complications (either medical or surgical) occurred in 10 patients following the PRS treatment (Table 2). Three patients (27%) developed a major wound complication (requiring surgical intervention), caused by necrosis or ischemia of the wound or surgical flap reconstruction. In one of these patients a lower limb amputation had to be performed due to ischemia causing an on-going secondary infection of the plastic surgery reconstruction. The median OTT for the PRS patients was 56 (49-69) days.

Discussion
The current study shows that the combination of neoadjuvant HILP and preoperative EBRT is feasible in locally advanced ESTS. Over the past decades the limb saving treatment for locally advanced ESTS has evolved greatly, and new treatment strategies in ESTS treatment have been developed with the goal to improve outcome and/or to decrease morbidity. First, the addition of postoperative EBRT to HILP and delayed surgical resection resulted in a significant improvement in local control without increasing morbidity in ESTS patients. Moreover, a follow-up study showed that dose reduction and a shorter HILP duration was safe and effective for patient outcome, as the 5-year local control rates and (limb) survival were not compromised. HILP followed by delayed surgical resection and postoperative EBRT when indicated is commonly used and accepted throughout Europe to achieve local tumor control and limb salvage in locally advanced ESTS. This results in a limb salvage rate of approximately 80-90% in patients who would otherwise be considered for amputation. A systematic review by Bhangu et al. reported a limb salvage rate of 81%.
3. A new limb saving treatment strategy for locally advanced sarcomas

The oncological outcome for patients following the PRS treatment regimen i.e. limb salvage rate of 91%, local recurrence rate of 9%, distant failure rate of 45% and disease-specific survival of 73% seems to be comparable with the oncological outcome as reported in the literature.8,9,12,29-32

The subtle higher limb salvage rate in the current study might be due to the relatively short follow-up. This might also account for the lower local recurrence rate and higher disease specific survival rate in the current study. However, the difference in local recurrence rate might also be caused by the consequent use of preoperative EBRT in the current series. Postoperative EBRT following HILP and delayed surgical resection was shown to improve the local tumor control in locally advanced ESTS, whereas the timing of EBRT does not seem to influence the oncological outcome in resectable ESTS.33-36 The distant failure rate in the current series (45%) seems similar to the 40% previously reported.29 However, due to the small sample size and relative short follow-up, the current results should be interpreted with some caution and they need further confirmation in larger patient-cohorts.

The major wound complication risk found in the current study seems to be comparable with earlier reported data, which showed that 26% of patients required re-operation, re-intervention or deep wound packing due to a wound complication, after surgical resection following isolated limb perfusion.31 The subtle higher percentage in the current study might be related to the intensified and shortened treatment course, whereas the administration of EBRT in the preoperative setting in the PRS treatment regimen might also play a role.33

Table 1. Patient and tumor characteristics

<table>
<thead>
<tr>
<th>Patient</th>
<th>Gender</th>
<th>Age</th>
<th>Histopathologic findings</th>
<th>Location</th>
<th>Tumor size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>32</td>
<td>Synovial sarcoma</td>
<td>Upper leg</td>
<td>6</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>41</td>
<td>Synovial sarcoma</td>
<td>Lower leg</td>
<td>4</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>74</td>
<td>Pleomorphic undifferentiated sarcoma</td>
<td>Upper leg</td>
<td>10</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>54</td>
<td>Pleomorphic undifferentiated sarcoma</td>
<td>Upper leg</td>
<td>17</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>63</td>
<td>Pleomorphic undifferentiated sarcoma</td>
<td>Lower leg</td>
<td>9</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>71</td>
<td>Myxofibrosarcoma</td>
<td>Upper leg</td>
<td>5</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>44</td>
<td>Myxofibrosarcoma</td>
<td>Upper leg</td>
<td>17</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>74</td>
<td>Pleomorphic undifferentiated sarcoma</td>
<td>Knee</td>
<td>7</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>64</td>
<td>Leiomyosarcoma</td>
<td>Knee</td>
<td>6</td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>75</td>
<td>Pleomorphic undifferentiated sarcoma</td>
<td>Lower leg</td>
<td>8</td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>67</td>
<td>Leiomyosarcoma</td>
<td>Knee</td>
<td>6</td>
</tr>
</tbody>
</table>

Age at start of treatment (years). Tumor size: maximum diameter (cm) at preoperative MRI-scan.

Table 2. Complications following PRS treatment

<table>
<thead>
<tr>
<th>Total amount of complications</th>
<th>PRS (n=11)</th>
<th>Complication grade according to Clavien-Dindo22</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical</td>
<td>3 (21%)</td>
<td>I-IIIb</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>1 II</td>
<td></td>
</tr>
<tr>
<td>Urinary retention</td>
<td>2 I</td>
<td></td>
</tr>
<tr>
<td>Surgical</td>
<td>11 (79%)</td>
<td></td>
</tr>
<tr>
<td>Seroma</td>
<td>2 I</td>
<td></td>
</tr>
<tr>
<td>Rash following melphalan administration</td>
<td>1 I</td>
<td></td>
</tr>
<tr>
<td>Wound infection needing intravenous antibiotics</td>
<td>1 II</td>
<td></td>
</tr>
<tr>
<td>Deep venous thrombosis</td>
<td>1 II</td>
<td></td>
</tr>
<tr>
<td>Cellulitis needing intravenous antibiotics</td>
<td>3 II</td>
<td></td>
</tr>
<tr>
<td>Wound infection</td>
<td>1 IIIb</td>
<td></td>
</tr>
<tr>
<td>Partial flap loss</td>
<td>2 IIIb</td>
<td></td>
</tr>
</tbody>
</table>

Patients developing a complication 10 (91%)
Patients developing a major wound complication 3 (27%)

Major wound complication: wound complication occurring during treatment or <120 days of surgical resection requiring surgical intervention. Abbreviation: PRS=perfusion, preoperative radiotherapy and surgery.
Due to tumor heterogeneity in STS, tumor necrosis present prior to the start of treatment cannot be distinguished from tumor necrosis induced by neoadjuvant treatment, possibly leading to an overestimation of the effect of neoadjuvant treatment. Therefore, the effectiveness of neoadjuvant treatment, based on tumor necrosis, reported in previous studies, including UMCG HILP series, might be questioned and tumor necrosis should not be used when making treatment decisions. Moreover, the tumor response can differ throughout these heterogeneous tumors while the tumor response at the closest surgical margin might have the most predictive value for local recurrence. In 2016, this led to a proposal for the standardization of the histopathologic examination of STS by the EORTC-STBSG. This protocol included a STS response score in which the tumor response to neoadjuvant treatment is estimated according to the proportion of stainable tumor cells. A recent study did not find an association between the STS response score and survival following preoperative EBRT and surgical resection. However, further studies considering local control and survival are necessary.

Postoperative EBRT in ESTS is characterized by long treatment times and high doses of radiotherapy resulting in increased long-term morbidity when compared with preoperative EBRT. Furthermore, the conventional HILP treatment is extensive, long lasting and includes long waiting periods between the different treatment stages (i.e. 6-8 weeks between the HILP and surgical resection, and another 6-8 weeks between the surgical resection and the start of postoperative EBRT). Despite the higher major wound complication risk incorporated with preoperative EBRT, a tendency towards the use of preoperative EBRT seems to have originated in the treatment of resectable ESTS. As mentioned, the standard preoperative EBRT dose in ESTS treatment is 50 Gy in 25 daily fractions of 2 Gy nowadays. In the past various preoperative hypofractionated EBRT regimens, 10x3.5 Gy, 10x3 Gy, 5x3.5 Gy and 8x3.5 Gy, combined with neoadjuvant chemotherapy have been conducted and resulted in acceptable local control rates. Recently, the oncological outcome in resectable ESTS and trunk STS following 5x5 Gy hypofractionated preoperative EBRT was found to be comparable with the onco-

Table 3. Treatment results and oncological outcome

<table>
<thead>
<tr>
<th>Patient</th>
<th>Histopathologic response Grade*</th>
<th>R-status#</th>
<th>Local recurrence</th>
<th>Distant metastases</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>C</td>
<td>R0</td>
<td>No</td>
<td>No</td>
<td>Alive without disease</td>
</tr>
<tr>
<td>2</td>
<td>D</td>
<td>R0</td>
<td>No</td>
<td>Yes</td>
<td>Died of disease</td>
</tr>
<tr>
<td>3</td>
<td>D</td>
<td>R0</td>
<td>No</td>
<td>No</td>
<td>Alive without disease</td>
</tr>
<tr>
<td>4</td>
<td>D</td>
<td>R1</td>
<td>No</td>
<td>Yes</td>
<td>Died of disease</td>
</tr>
<tr>
<td>5</td>
<td>A</td>
<td>R0</td>
<td>Yes</td>
<td>Yes</td>
<td>Died of disease</td>
</tr>
<tr>
<td>6</td>
<td>E</td>
<td>R1</td>
<td>No</td>
<td>No</td>
<td>Alive without disease</td>
</tr>
<tr>
<td>7</td>
<td>D</td>
<td>R0</td>
<td>No</td>
<td>Yes</td>
<td>Alive with disease</td>
</tr>
<tr>
<td>8</td>
<td>B</td>
<td>R0</td>
<td>No</td>
<td>No</td>
<td>Alive without disease</td>
</tr>
<tr>
<td>9</td>
<td>D</td>
<td>R1</td>
<td>No</td>
<td>Yes</td>
<td>Alive with disease</td>
</tr>
<tr>
<td>10</td>
<td>E</td>
<td>R1</td>
<td>No</td>
<td>No</td>
<td>Alive without disease</td>
</tr>
<tr>
<td>11</td>
<td>C</td>
<td>R2</td>
<td>No</td>
<td>No</td>
<td>Alive without disease</td>
</tr>
</tbody>
</table>

*Histopathologic response Grade A, no stainable tumor cells left; Grade B, single stainable tumor cells or small clusters (overall <1% left); Grade C, ≥1% - 10% stainable tumor cells left; Grade D, ≥10% - <50% stainable tumor cells left; and Grade E, ≥50% stainable tumor cells left. #R-status.
logical outcome following the commonly used 25x2 Gy regimen. Furthermore, only 7% of the patients in the 5x5 Gy study developed a wound complication requiring a surgical intervention. Dose reduction and hypofractionation in localized myxoid liposarcomas is under ongoing investigation and the first results of the DOREMY-study (NCT02106312) are awaited. These new hypofractionated preoperative EBRT schemes might lead to a further reduction in wound complication risk.

In summary, the results of the current study indicate that combining HILP and preoperative hypofractionated EBRT as neoadjuvant treatment is feasible and might further improve the treatment of patients with locally advanced ESTS without increasing the risk of local failure.

**Conclusion**

This study demonstrates that the intensive PRS treatment regimen is feasible and safe in locally advanced ESTS. The PRS treatment which combines neoadjuvant HILP and preoperative EBRT, achieves oncological results that are comparable with oncological outcome from earlier reported data. In addition, the major wound complication risk is comparable and the overall treatment time is reduced.

**References**

3. A new limb saving treatment strategy for locally advanced sarcomas


